title: Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.
authors.affiliation: Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. amoss@bidmc.harvard.edu.
authors.forename: A C
authors.initials: AC
authors.lastname: Moss
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D003424:Crohn Disease / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized